ASCO 2016 | Phase III METEOR trial: cabozantinib vs everolimus for advanced clear cell renal cell carcinoma
Toni Choueiri, MD of the Dana-Farber Cancer Center, Boston, MA discusses the Phase III METEOR randomized clinical trial of cabozantinib vs everolimus in advanced clear cell renal cell carcinoma (ccRCC) (NCT01865747). This trial randomized patients to everolimus on a standard dose of 10 mg/day or cabozantinib, which was administered at a dose of 60 mg/day. Cabozantinib is a multi-tyrosine kinase inhibitor that offers inhibition of the vascular endothelial growth factor (VEGF) receptor. There was a 1:1 randomization between cabozantinib and everolimus. The primary endpoint of the study of progression-free survival (PFS) was met, and he mentions that the results were published in the New England Journal of Medicine last year. At ASCO 2016, he will be presenting the key secondary endpoints of overall survival (OS), which was also met, with an almost 5-month difference in survival between the everolimus and cabozantinib arm.
Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.
Get great new content delivered to your inboxSign up